Surprisingly, Tsao et al. [31] unveiled that this compound posed inhibitory activities against diverse NSCLC cells (i.e., A549, H3255, and Calu-6), while the underlying molecular mechanisms involved the modulation of FAK, MAPK, and NF-κB pathways. Here, PTK2 is linked to non-small cell lung carcinoma.